

# Addiction Medicine Seeks ABMS Recognition

BY DAMIAN McNAMARA  
Miami Bureau

MIAMI — The field of addiction medicine is preparing to take a major step to enhance its authority and expand its professional ranks.

The American Society of Addiction Medicine plans to form a certification board and seek official recognition from the American Board of Medical Specialties by the end of 2007, physicians said during a panel presentation at the society's annual conference.

Addiction medicine is self-designated as a specialty, "but we need acceptance from all medicine," ASAM President-Elect Michael M. Miller said, explaining the plan to offer ABMS-recognized certification in addiction medicine. "Patients need to know where to find a doctor who does this, to be assured this doctor has a full array of training and ... has passed an examination."

The anticipated American Board of Addiction Medicine is likely to involve an alliance with one or more of the existing ABMS specialty boards. Details about the board and its relationship with existing boards are being worked out. (See box.)

"There is no other way to do this than to work with psychiatry, internal medicine, family medicine, and other specialists," said Dr. Kevin Kunz, an addiction medicine specialist in Kona, Hawaii, and cochair of the ASAM Medical Specialty Action Group.

"The need for addiction medicine as a specialty is widely recognized," Dr. Kunz said. "The science is exploding, and new therapies are available—both biologic and behavioral," he said. Also, "better funding is possible. Policy makers are understanding that addiction is a disease and treatable."

As part of the effort, trauma surgeons and emergency physicians also may be consulted, said Dr. Miller, medical director of the NewStart Alcohol/Drug Treatment Program at Meriter Hospital, Madison, Wis. Dr. Miller recently stepped down as cochair of the action group.

A key goal is to expand addiction medicine training beyond addiction psychiatry, said Dr. R. Jeffrey Goldsmith, professor of clinical psychiatry at the University of Cincinnati. "We don't fill all our current addiction psychiatry spots. Psychiatry is not as enthusiastic as I would like," he said. A total of 55 of the 116 total approved addiction psychiatry residency spots were filled in 2005-2006, according to data from the Accreditation Council for Graduate Medical Education.

Most current ASAM members have board certification in an ABMS-recognized specialty, including 27% who are certified in psychiatry and 26% who are certified in primary care specialties (13% in family medicine, 12% in internal medicine, and 1% in pediatrics).

No specialty board represents addiction medicine, so the 4,162 physicians who have passed the ASAM's certification examination in addiction medicine cannot describe themselves as board certified in this field.

Board certification in addiction medicine "will give me more stature among my colleagues," said Dr. Mark L. Kraus, an internist whose group practice in Water-

bury, Conn., is a referral center for patients with substance abuse disorders. He is a newly elected member of the ASAM board of directors.

"Every primary care physician has to know how to do screening and brief interventions," said Dr. David Lewis, an internist who is a professor of community health and medicine, and a professor of alcohol and addiction studies, at Brown University, Providence, R.I.

Patient referral "is where the specialty

of addiction medicine and certification come in," he said.

Dr. Kraus agreed: "Without a doubt, this [plan to seek ABMS recognition] will enhance care. ... Designated specialists who have learned the evidence-based medicine ... can help all primary care docs when they need to take their patient to the next level."

Dr. Kraus noted that "the government, the Institute of Medicine, the American Medical Association, and some insurance companies are recognizing addiction med-

icine. There are a lot of outside influences that will help us."

Two pending bills—one in the House of Representatives and one in the Senate—would provide reimbursement for addiction treatment on a level equal to that for treatment of other medical conditions. Parity in compensation would make it easier to maintain a practice that emphasizes addiction medicine and would help attract more young physicians to the field, Dr. Kraus said. ■

*ZEGERID is the only oral PPI that combines*

## Immediate release with the POWER of continued acid control

### Rapid Release

➤ Peak plasma levels reached in **~30 minutes**<sup>1,2</sup>

### Continued Control

➤ Gastric pH >4 maintained for a median of **18.6 hours**<sup>2,\*†</sup>

➤ Effective nighttime acid control<sup>3,4‡</sup>

### The correlation of pharmacodynamic data to clinical effect has not been established.

<sup>1</sup>This pharmacodynamic study measured the median percentage of time gastric pH >4 as 18.6 hours over 24 hours with ZEGERID 40 mg Powder for Oral Suspension in healthy subjects (N=24).

<sup>2</sup>Median values for the time gastric pH >4 for patients taking ZEGERID Powder for Oral Suspension and Capsules, 20 mg and 40 mg doses, ranged from 12.2 to 18.6 hours on Day 7.

<sup>†</sup>Powder for oral suspension.

<sup>‡</sup>Gastric pH >4 ranged from 12.2 to 18.6 hours on Day 7.<sup>3</sup>

#### Indications and Dosing for ZEGERID

ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) (20 mg QD); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy (20 mg QD); for maintenance of healing of erosive esophagitis (20 mg QD) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg QD); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg QD); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg/1680 mg QD; use beyond 14 days has not been evaluated).

#### Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In critically ill patients treated with ZEGERID, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID and with the comparator (acid-controlling) drug. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.



## Logistics of New Addiction Medicine Board Are Likely to Evolve Over Time

The planned addiction medicine board may start out as a conjoint board that is tied to existing boards, according to American Society of Addiction Medicine leaders.

The new board could eventually evolve into an independent one, in the same way that emergency medicine and nuclear medicine did after functioning for an average of 12 years as conjoint boards.

Of the 24 member boards of the

American Board of Medical Specialties (ABMS), 23 are primary, meaning that they include members from that specialty only. The only exception is the American Board of Allergy and Immunology, formed in 1971 and the only current conjoint board.

There are 75 ABMS-recognized subspecialties. The newest are hospice and palliative care (pending) and sleep medicine (2006). There is also a precedent for subspecialty fields to evolve to become

primary boards, such as radiology.

"We realized addiction medicine would not become a primary board. It would be difficult because of the huge cost involved and a perception of taking physicians from other specialties," Dr. Kunz said.

The last specialty to form a primary board at inception was medical genetics, which formed in 1991 after 26 years as a self-regulated board.

"Whatever we come up with, we will

have to develop a grandfather clause. But it will still have to meet ACGME [Accreditation Council for Graduate Medical Education] and ABMS criteria," Dr. Goldsmith said.

There are big challenges ahead, he said. "What happens to people with ASAM credentials today? How will we grandfather them in?" He added, "But we realize that an ABMS-recognized specialty of addiction medicine is exactly the direction we need to go."

**First and Only Immediate-Release oral PPI**

**Zegerid<sup>®</sup>**  
omeprazole/sodium bicarbonate

ZEGERID Capsules contain 300 mg of sodium per dose in the form of sodium bicarbonate (1100 mg/13 mEq). ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose in the form of sodium bicarbonate (1680 mg/20 mEq). This should be taken into consideration for patients on a sodium-restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation. Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

Please see brief summary of full Prescribing Information on the following page.

References: 1. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. *Expert Opin Pharmacother*. 2005;6:2501-2510. 2. ZEGERID Prescribing Information. Santarus, Inc. February 2006. 3. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther*. 2007;25:197-205. 4. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther*. 2005;21:1467-1474.

For more information, visit us at [www.zegerid.com](http://www.zegerid.com).